Evaluating Women With Ovarian Cancer for BRCA1 and BRCA2 Mutations: Missed Opportunities

被引：0
|
作者：
Herman, Jonathan [1 ]
机构：
[1] Long Isl Jewish Med Ctr, New York, NY USA
来源：
OBSTETRICS AND GYNECOLOGY | 2010年 / 116卷 / 02期
关键词：
D O I：
10.1097/AOG.0b013e3181eaa0c0
中图分类号：
R71 [妇产科学];
学科分类号：
100211 ;
摘要：
引用
收藏
页码：440 / 441
页数：5
相关论文
共 50 条
  • [1] Evaluating Women With Ovarian Cancer for BRCA1 and BRCA2 Mutations Missed Opportunities
    Meyer, Larissa A.
    Anderson, Meaghan E.
    Lacour, Robin A.
    Suri, Anuj
    Daniels, Molly S.
    Urbauer, Diana L.
    Nogueras-Gonzalez, Graciela M.
    Schmeler, Kathleen M.
    Gershenson, David M.
    Lu, Karen H.
    [J]. OBSTETRICS AND GYNECOLOGY, 2010, 115 (05): : 945 - 952
  • [2] Evaluating Women With Ovarian Cancer for BRCA1 and BRCA2 Mutations: Missed Opportunities Reply
    Lu, Karen H.
    [J]. OBSTETRICS AND GYNECOLOGY, 2010, 116 (02): : 441 - 441
  • [3] Evaluating Women With Ovarian Cancer for BRCA1 and BRCA2 Mutations Missed Opportunities EDITORIAL COMMENT
    Meyer, Larissa A.
    Anderson, Meaghan E.
    Lacour, Robin A.
    Suri, Anuj
    Daniels, Molly S.
    Urbauer, Diana L.
    Nogueras-Gonzalez, Graciela M.
    Schmeler, Kathleen M.
    Gershenson, David M.
    Lu, Karen H.
    [J]. OBSTETRICAL & GYNECOLOGICAL SURVEY, 2010, 65 (07) : 436 - 437
  • [4] BRCA1 and BRCA2 Mutations in Ovarian Cancer
    Buerkle, Bernd
    Tempfer, Clemens
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (04): : 359 - 359
  • [5] Evaluating women with ovarian cancer for BRCA1 and BRCA2 mutations: A trend over time
    Meyer, L. A.
    Anderson, M. E.
    Lacour, R. A.
    Westin, S. N.
    Burzawa, J. K.
    Urbauer, D. L.
    Daniels, M. S.
    Burke, C. C.
    Gershenson, D. M.
    Lu, K. H.
    [J]. GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S96 - S97
  • [6] BRCA1 and BRCA2 Mutations in Ovarian Cancer Reply
    Zhang, Wei
    Yang, Da
    Sood, Anil K.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (04): : 360 - 361
  • [7] Evaluating women with ovarian cancer for BRCA 1/2: Missed opportunities
    Meyer, L.
    Westin, S. N.
    Lacour, R. A.
    Urbauer, D. L.
    Schmeler, K. M.
    Daniels, M. S.
    Sun, C. C.
    Gershenson, D. M.
    Lu, K. H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [8] Evaluating women with ovarian cancer for BRCA 1/2: missed opportunities
    Meyer, L. A.
    Westin, S. N.
    Lacour, R. A.
    Urbauer, D. L.
    Sun, C. C.
    Daniels, M. S.
    Schmeler, K. M.
    Gershenson, D. M.
    Lu, K. H.
    [J]. GYNECOLOGIC ONCOLOGY, 2008, 108 (03) : S67 - S68
  • [9] Rucaparib for recurrent ovarian cancer with BRCA1 and BRCA2 mutations
    Ganguly, Shuvadeep
    Gogia, Ajay
    [J]. LANCET ONCOLOGY, 2022, 23 (07): : E314 - E314
  • [10] Unwrapping the Implications of BRCA1 and BRCA2 Mutations in Ovarian Cancer
    Hyman, David M.
    Spriggs, David R.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2012, 307 (04): : 408 - 410
12345